US FDA
FD&C Act Section 506C - Drug Shortages Reporting
Plain-language explanation, inspection context and common violation patterns.
What it says
Manufacturers of certain drugs must notify FDA of a permanent discontinuance or an interruption in manufacturing likely to lead to a meaningful disruption in supply, with notification generally required at least six months in advance where possible, allowing FDA to work with manufacturers and identify alternative supply sources before a shortage actually affects patient access.
Paraphrased for plain-language clarity. Always verify against the current published regulation text.
What it means in practice
- This provision reflects a supply chain resilience and patient access concern distinct from the product quality focus of most other regulations in this library, requiring manufacturers to proactively flag supply risk rather than only reporting quality problems.
- The notification obligation applies not just to complete discontinuation but to manufacturing interruptions likely to meaningfully disrupt supply, meaning a significant facility issue, equipment failure, or raw material shortage can trigger this reporting obligation even without a formal decision to discontinue the product.
- Advance notification, ideally six months where feasible, gives FDA time to work with the manufacturer or identify alternative sources, meaning delayed notification undermines the entire purpose of this proactive early-warning system.
What FDA inspectors look for
- Whether manufacturing disruptions with genuine potential to meaningfully affect supply were identified and assessed for reportability under this provision in a timely manner.
- Whether notification, when required, was provided with adequate advance notice rather than only after a shortage has already begun to affect patient access.
- This is primarily a supply chain risk notification obligation rather than a specific manufacturing practice, though its effectiveness depends on the underlying manufacturing risk monitoring and escalation processes actually identifying reportable events promptly.
Most common violation
A manufacturing interruption with genuine potential for meaningful supply disruption not identified and escalated internally with enough lead time to provide the advance notification this provision is intended to enable.
Want a deeper, interactive breakdown?
GMPify's Regulation Explainer tool gives subscribers an AI-powered analysis of any 21 CFR, EU GMP, USP or ICH reference, with live inspection context.
Try the Regulation Explainer →